Last updated on November 2019

A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial


Brief description of study

This is a single-arm, multi-center, open-label extension study designed to provide pertuzumab to patients who continue to derive benefit from pertuzumab, as well as to collect long-term safety and efficacy data of pertuzumab therapy. Patients receiving pertuzumab as an investigational medicinal product (IMP) in a Roche-sponsored Global study who continue to receive pertuzumab at the time of the Parent study end are eligible for continued treatment in this extension study. Patients with solid tumors who have not experienced progressive disease in the Parent study and, in the Investigator's opinion, may potentially benefit from continued Perjeta treatment will continue to receive pertuzumab until disease progression, unacceptable toxicities, Investigator decision, patient non-compliance, patient death, patient request to withdraw, or study termination by the Sponsor.

Clinical Study Identifier: NCT02320435

Find a site near you

Start Over